Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-γ ligand therapy

Circulation Research

Volumn 91, Issue 3, 2002, Pages 210-217

  Bishop Bailey, David ^a   Hla, Timothy ^a   Warner, Timothy D ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Atherosclerosis; Cyclooxygenase 2; Intimal smooth muscle cells; Peroxisome proliferator activated receptor ; Restenosis

Indexed keywords

ARACHIDONIC ACID; CD36 ANTIGEN; CELL NUCLEUS RECEPTOR; CYCLOOXYGENASE 2; ICOSANOID; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TRANSCRIPTION FACTOR;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CELL DEATH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE ACTIVATION; GENE TARGETING; HUMAN; HUMAN CELL; INTIMA; PRIORITY JOURNAL; RECEPTOR GENE; RESTENOSIS; SMOOTH MUSCLE FIBER; VASCULAR DISEASE;

ANIMALS; ANTIGENS, CD36; ARTERIAL OCCLUSIVE DISEASES; CELL LINE; CELLS, CULTURED; CYCLOOXYGENASE 2; DRUG DELIVERY SYSTEMS; ISOENZYMES; LIGANDS; MALE; MUSCLE, SMOOTH, VASCULAR; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; RNA, MESSENGER; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TUNICA INTIMA; TUNICA MEDIA;

EID: 0037047666     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000029080.15742.85     Document Type: Article

References (52)

1. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors
2. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists
3. Peroxisome proliferator-activated receptors in the cardiovascular system
4. Peroxisome proliferator-activated receptors: A nuclear receptor signaling pathway in lipid physiology
5. Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor-γ ligands and agonists
6. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
7. Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells
8. PPARγ-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells
9. 2
10. Peroxisome proliferator-activated receptor-γ ligands are potent inhibitors of angiogenesis in vitro and in vivo
11. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
12. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
13. The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses
14. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor-γ (PPARγ) agonists. PPARγ co-association with transcription factor NFAT
15. Expression of the peroxisome proliferator-activated receptor-γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
16. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL
17. Expression and function of PPARγ in rat and human vascular smooth muscle cells
18. Peroxisome proliferator-activated receptor-γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
19. Smooth muscle diversity in arterial wound repair
20. Rat carotid neointimal smooth muscle cells reexpress a developmentally regulated mRNA phenotype during repair of arterial injury
21. Plasminogen activator expression in rat arterial smooth muscle cells depends on their phenotype and is modulated by cytokines
22. Production of platelet-derived growth factor-like molecules by cultured arterial smooth muscle cells accompanies proliferation after arterial injury
23. Rat aortic smooth muscle cells isolated from different layers and at different times after endothelial denudation show distinct biological features in vitro
24. Cellular retinol-binding protein-1 is expressed by distinct subsets of rat arterial smooth muscle cells in vitro and in vivo
25. Smooth muscle cell heterogeneity: Patterns of gene expression in vascular smooth muscle cells in vitro and in vivo
26. Characterization of cloned aortic smooth muscle cells from young rats
27. Cyclo-oxygenase-2 in vascular smooth muscle
28. Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat aorta in organ culture
29. Differential induction of cyclooxygenase-2 in human arterial and venous smooth muscle: Role of endogenous prostanoids
30. Bisphenol A diglycidyl ether (BADGE) is a PPARγ agonist in an ECV304 cell line
31. Fatty acid translocase/CD36 mediates the uptake of palmitate by type II pneumocytes
32. Restoration of prostacyclin synthase in vascular smooth muscle cells after aspirin treatment: Regulation by epidermal growth factor
33. Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty
34. The role of PPAR-γ in macrophage differentiation and cholesterol uptake
35. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
36. A peroxisome proliferator-activated receptor-γ ligand inhibits adipocyte differentiation
37. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs
38. Peroxisome proliferator-activated receptor γ ligands inhibit retinoblastoma phosphorylation and G1-> S transition in vascular smooth muscle cells
39. Peroxisome proliferator-activated receptor-γ activators down-regulate angiotensin II type 1 receptor in vascular smooth muscle cells
40. Expression of macrophage (Mphi) scavenger receptor, CD36, in cultured human aortic smooth muscle cells in association with expression of peroxisome proliferator activated receptor-γ, which regulates gain of Mphi-like phenotype in vitro, and its implication in atherogenesis
41. 2 gene in vascular smooth muscle cells by a nuclear factor κB and peroxisome proliferator-activated receptor-mediated process
42. Differential activation of adipogenesis by multiple PPAR isoforms
43. DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5′-flanking region
44. Peroxisome proliferator-activated receptor γ-mediated transcriptional up-regulation of the hepatocyte growth factor gene promoter via a novel composite cis-acting element
45. Dual DNA-binding specificity of peroxisome-proliferator-activated receptor γ controlled by heterodimer formation with retinoid X receptor α
46. Ligand type-specific interactions of peroxisome proliferator-activated receptor γ with transcriptional coactivators
47. A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity
48. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages
49. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions
50. Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells
51. Induction of cyclooxygenase-2 in human saphenous vein and internal mammary artery
52. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor-γ